Pei Xiang Xing
Cancer Immunotherapy Laboratory
Austin Research Institute
Heidelberg
Victoria
Australia
Name/email consistency: high
- Cripto: a novel target for antibody-based cancer immunotherapy. Xing, P.X., Hu, X.F., Pietersz, G.A., Hosick, H.L., McKenzie, I.F. Cancer Res. (2004)
- Technology evaluation: R-1549, Antisoma/Roche. Xing, P.X. Curr. Opin. Mol. Ther. (2003)









